| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1158/1078-0432.CCR-09-1834 |
| P698 | PubMed publication ID | 20634194 |
| P2093 | author name string | Erica L Mayer | |
| Ian E Krop | |||
| P2860 | cites work | Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 3526-3532 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Advances in targeting SRC in the treatment of breast cancer and other solid malignancies | |
| P478 | volume | 16 |
| Q50041888 | A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. |
| Q27335593 | A novel 3D fibril force assay implicates src in tumor cell force generation in collagen networks |
| Q36276485 | A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer |
| Q37494943 | Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop |
| Q24300885 | Activation of rapid oestrogen signalling in aggressive human breast cancers |
| Q54610139 | Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance. |
| Q39108742 | Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells |
| Q34658293 | Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study |
| Q35995710 | C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway |
| Q41144896 | CXCL12/SDF-1α induces migration via SRC-mediated CXCR4-EGFR cross-talk in gastric cancer cells |
| Q39120121 | Caffeic acid regulates LPS-induced NF-κB activation through NIK/IKK and c-Src/ERK signaling pathways in endothelial cells |
| Q35992390 | Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway |
| Q34100838 | Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer |
| Q37338907 | Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers |
| Q34708878 | Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. |
| Q35919774 | Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling |
| Q35050239 | Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium |
| Q39160945 | Dasatinib inhibits mammary tumour development in a genetically engineered mouse model |
| Q93350819 | Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells |
| Q28546078 | Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia |
| Q26825584 | Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer |
| Q58763841 | Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis |
| Q40196342 | Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma. |
| Q38965929 | Elucidation of epithelial-mesenchymal transition-related pathways in a triple-negative breast cancer cell line model by multi-omics interactome analysis. |
| Q38055272 | Emerging molecular targets in melanoma invasion and metastasis |
| Q38086421 | Emerging targeted agents in metastatic breast cancer |
| Q98665166 | Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis |
| Q36732781 | Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. |
| Q34972855 | From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond |
| Q37850683 | From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management |
| Q38989597 | Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. |
| Q36153325 | Identification of new candidate therapeutic target genes in triple-negative breast cancer |
| Q39434943 | Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells |
| Q56962519 | Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells |
| Q37605645 | Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets. |
| Q91825069 | Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells |
| Q37672635 | Invading one step at a time: the role of invadopodia in tumor metastasis |
| Q41536100 | Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. |
| Q35779175 | Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis |
| Q33786788 | Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice |
| Q57784935 | Monitoring Src status after dasatinib treatment in HER2+ breast cancer with Zr-trastuzumab PET imaging |
| Q39360651 | Multidrug-resistant cells overexpressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity |
| Q36665708 | Novel therapies for the treatment of advanced prostate cancer |
| Q41425790 | Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer |
| Q41233146 | P-glycoprotein attenuates DNA repair activity in multidrug-resistant cells by acting through the Cbp-Csk-Src cascade |
| Q36290579 | Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts |
| Q54572400 | Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors. |
| Q54114959 | Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. |
| Q24301920 | Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor |
| Q48505210 | Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer |
| Q28243770 | Regulation of SRC family kinases in human cancers |
| Q53352729 | Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma. |
| Q27016629 | Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies |
| Q49887894 | Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. |
| Q35803670 | SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer |
| Q37193756 | SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. |
| Q55454920 | Src Plays an Important Role in AGE-Induced Endothelial Cell Proliferation, Migration, and Tubulogenesis. |
| Q41224540 | Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation |
| Q46851492 | Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis |
| Q49787703 | Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action |
| Q35371875 | Src regulates Tyr(20) phosphorylation of transferrin receptor-1 and potentiates breast cancer cell survival |
| Q47608480 | Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase |
| Q38700342 | Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases |
| Q38009760 | Targeted therapy for triple-negative breast cancer: where are we? |
| Q27025646 | Targeting Src family kinases in anti-cancer therapies: turning promise into triumph |
| Q35640216 | Targeting invadopodia to block breast cancer metastasis |
| Q98466261 | Targeting the Extra-Cellular Matrix-Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors |
| Q38981265 | The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer |
| Q43184281 | The potential of Src inhibitors |
| Q30010212 | The regulation of N-methyl-D-aspartate receptors by Src kinase. |
| Q35149569 | The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma |
| Q64062159 | Therapeutic Targeting of Collective Invasion in Ovarian Cancer |
| Q37931268 | Therapeutic pipeline for soft-tissue sarcoma |
| Q38088419 | Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development |
| Q39614066 | Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy |
| Q83810300 | Trastuzumab resistance: all roads lead to SRC |
| Q88368631 | Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model |
| Q34125340 | Trihydrophobin 1 phosphorylation by c-Src regulates MAPK/ERK signaling and cell migration |
| Q30658863 | Tyr724 phosphorylation of ELMO1 by Src is involved in cell spreading and migration via Rac1 activation |
| Q38772631 | UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer |
| Q34795271 | Unliganded estrogen receptor alpha promotes PC12 survival during serum starvation |
| Q90523430 | Unraveling the Cellular Mechanism of Assembling Cholesterols for Selective Cancer Cell Death |
| Q31103913 | Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets |
| Q54977387 | YAP/TAZ Activation as a Target for Treating Metastatic Cancer. |
| Q89746413 | YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression |
| Q96640911 | YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer |
| Q34472383 | p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. |
Search more.